No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GOSS Gossamer Bio
- 0.639
- -0.032-4.70%
Close May 22 16:00 ET
144.44MMarket Cap-751P/E (TTM)
0.690High0.630Low1.49MVolume0.685Open0.670Pre Close971.09KTurnover0.79%Turnover RatioLossP/E (Static)226.22MShares1.88052wk High5.41P/B121.55MFloat Cap0.45352wk Low--Dividend TTM190.37MShs Float27.150Historical High--Div YieldTTM8.94%Amplitude0.453Historical Low0.650Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price target.
Express News | Gossamer Bio to Provide Updated Seralutinib Torrey Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
PDF Version SAN DIEGO--(BUSINESS WIRE)--May 14, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ
Express News | Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Comments
$Gossamer Bio(GOSS.US$ Hold tight one dollar soon
$Gossamer Bio(GOSS.US$ Gossamer Bio Inc: $396 Mln in Cash, Cash Equivalents & Marketable Securities, as of March 31, 2024! Enough to fund operations into Q1 2027![]()
2
7
$Gossamer Bio(GOSS.US$ Really thought that this part of the deal ((( Chiesi will pay Gossamer $160 million as a development reimbursement. Additionally, Gossamer will be eligible to receive up to $146 million in regulatory milestones and $180 million in sales milestones. ))) Potentially 486M, woulda garnered a bit more attention? Well i like it and will continue adding on dips for now! Hehehe! NFA![]()
1
6
$Gossamer Bio(GOSS.US$ Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pah, Ph-Ild & Other Indications
Gossamer Bio Inc: Eligible to Receive up to $146 Mln in Regulatory and $180 Mln in Sales Milestones
Gossamer Bio Inc: Eligible to Receive up to $146 Mln in Regulatory and $180 Mln in Sales Milestones
3
12
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg